Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

US10995085B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Yongxin Han · Kirkland, CA
• Abdelghani Achab · Melrose, US
• Yongqi Deng · Newton, US
• Xavier Fradera · Brookline, US
• Craig R. Gibeau · Holliston, US
• Brett A. Hopkins · Stoughton, US
• Derun Li · Dedham, US
• Kun Liu · Edison, US
• Meredeth A. McGowan · Boston, US
• Nunzio Sciammetta · Sudbury, US
• David L. Sloman · Brookline, US
• Catherine White · Newton, US
• Hongjun Zhang · Waterloo, CA
• Hua Zhou · Acton, US

Key dates

• Filing date: Mar 16, 2020
• Grant date: May 4, 2021
• Expiry date: Mar 16, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.